{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for vitamin root_Display\ Name in Display Name (approximate match)
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Targeting alpha7 neuronal acetylcholine receptors (nAChRs) with selective agonists and positive allosteric modulators (PAMs) is considered a therapeutic approach for managing cognitive deficits in schizophrenia and Alzheimer's disease. A-867744 is a novel type II positive allosteric modulator of α7 nAChR, which was developed by Abbott Laboratories, and has a good potency and selectivity.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
A-836339 is a drug that acts as a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptor. It showed analgesic, anti-inflammatory and anti-hyperalgesic effects at low doses. A-836339 was detected in a certain product in Japan and was suggested to be for human consumption.
